紫杉醇或多西紫杉醇联合顺铂治疗晚期鼻咽癌的临床研究

A Clinical Research of Paclitaxel or Docetaxel Combined with Cisplatin in Treating Advanced Nasopharyneal Carcinoma

目的观察紫杉醇或多西紫杉醇联合顺铂治疗晚期鼻咽癌的疗效及安全性。方法随机将晚期鼻咽癌56例分为紫杉醇联合顺铂组(PP组)28例,多西紫杉醇联合顺铂组(DP组)28例。每例至少完成2周期以上的化疗。结果PP组有效率67.86%,中位缓解期10.7个月,中位生存期18.4个月。DP组有效率71.43%,中位缓解期11.8个月,中位生存期20.2个月。PP组较多出现肌肉骨关节痛和周围神经毒性;其他毒副反应为骨髓抑制和恶心、呕吐等,两组相近。结论紫杉醇或多西紫杉醇联合顺铂两方案治疗晚期鼻咽癌,效果较好,疗效相当,毒副反应均可耐受。

Objective To observe the efficacy and toxicities of paclitaxel or docetaxel combined with cisplatin for patients with advanced na- sopharyneal carcinoma. Methods 56 patients with advanced nasopharyneal carcinoma were randomized into two groups. The group PP （paclitaxel plus cisplatin） had 28 patients and the group DP （docetaxel plus cisplatin） had 28 patients too. The chemotherapy regimen was recycled at least more than two periods. Results The response rate （ CR ＋ PR） was 67.86% and 71.43% in the group PP and the group DP. The median duration of response was 10.7 and 11.8 months, the median survival of patients was 18.4 months and 20.2 months in the group PP and the group DP, respectively. Myalgia and neuro-sensory toxicity appeared more frequently in the group PP. The other toxicities of the both groups were myelosuppression, nausea and reaction of gastrointestinal tract. Conclusion The efficacy of paclitaxel or docetaxel plus cisplatin was the same. The toxicity is mild and tolerate.